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G-protein coupled receptorPathogenic Staphylococcus aureus strains produce N-formylmethionyl containing peptides, of which the
tetrapeptide fMIFL is a potent activator of the neutrophil formyl peptide receptor 1 (FPR1) and the PSMα2
peptide is a potent activator of the closely related FPR2. Variants derived from these two peptide activators
were used to disclose the structural determinants for receptor interaction. Removal of ﬁve amino acids from
the C-terminus of PSMα2 gave rise to a peptide that had lost the receptor-independent neutrophil
permeabilizing effect, whereas neutrophil activation capacity as well as its preference for FPR2 was retained.
Shorter peptides, PSMα21–10 and PSMα21–5, activate neutrophils, but the receptor preference for these peptides
was switched to FPR1.
The fMIFL-PSM5–16 peptide, in which the N-terminus of PSMα21–16 was replaced by the sequence fMIFL, was a
dual agonist for FPR1/FPR2, whereas fMIFL-PSM5–10 preferred FPR1 to FPR2. Further, an Ile residuewas identiﬁed
as a key determinant for interaction with FPR2. A chimeric receptor in which the cytoplasmic tail of FPR1 was
replaced by the corresponding part of FPR2 lost the ability to recognize FPR1 agonists, but gained function in
relation to FPR2 agonists.
Taken together, our data demonstrate that the C-terminus of the PSMα2 peptide plays a critical role for its
cytotoxicity, but is not essential for the receptor-mediated pro-inﬂammatory activity. More importantly, we
show that the amino acids present in the C-terminus, which are not supposed to occupy the agonist-binding
pocket in the FPRs, are of importance for the choice of receptor.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Peptides startingwith anN-formylatedmethionyl group constitute a
unique hallmark of bacterial as well as mitochondrial metabolism [1,2],
and professional phagocytes of our innate immune system recognizethe SwedishMedical Research
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hlgren).this microbial/mitochondrial pattern as a danger signal that guides in-
nate immune cells, such as neutrophil granulocytes, to infected/
inﬂamed tissues [3,4]. The molecular basis for this recognition
in neutrophils is the expression of pattern recognition receptors,
e.g., FPRs, for which the formylated methionyl group at the N-terminus
of the peptide is a critical determinant. These cell surface receptors
belong to the group of G-protein coupled receptors, a group that also
comprises other receptors expressed in neutrophils such as the recep-
tors for C5a (C5aR), LTB4 (BLT1), and PAF (PAFR) [5,6]. Human
neutrophils express two structurally very similar formyl peptide
receptors, FPR1 and FPR2 [6]. The precise biological roles of FPRs
are incompletely understood, but the identiﬁcation of both exogenous
and endogenous ligands involved in inﬂammation strongly indicates a
pivotal role of these receptors in regulating defense reactions and the
resolution of inﬂammation [5,7,8].
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share a high degree of amino acid identity and signaling properties
but they bind different agonists that either activate or inhibit
cellular functions depending on the triggering agonist [5]. FPR1 is
one of the best-characterized chemoattractant receptors for which
the Staphylococcus aureus-derived tetrapeptide fMIFL is a very
potent agonist and the Escherichia coli-produced attractant fMLF is
a slightly less potent agonist. The latter is a commonly used proto-
typic chemoattractant hardly recognized by FPR2 [5,6,9]. The ability
of this prototypic peptide and variants thereof to activate/bind the
wild type FPR1 and chimeric receptors, as well as receptor mutants
[10–12], has been the basis for deﬁning the structural demands for
ligand recognition by FPR1. The high-afﬁnity binding site in FPR1
for formylmethionyl peptides most likely involves multiple non-
contiguous residues that must be positioned by the proper folding
of all extracellular domains as well as the transmembrane parts in
the receptor [13,14]. The size of the proposed binding pocket that
is available for receptor agonists has been estimated to be limited
and comprises four or at the most ﬁve amino acids [15]. Virtually
no studies of structural demands for ligand recognition have been
performed with FPR2.
The short S. aureus-derived peptide fMIFL displays high-afﬁnity
binding to FPR1, but community-associated methicillin resistant
S. aureus strains (CA-MRSA) also secrete a group of somewhat longer
formylated peptides that interact primarily with FPR2 [16]. These
peptides belong to the family of phenol soluble modulins (PSM),
α-helical molecules with a high degree of amphipathicity, and they
are usually secreted from the bacteria without deformylation (removal
of the formyl group at the N-terminal methionine). All PSMα peptides
investigated have the same basic functions and they promote virulence
through effects on discrete neutrophil functions (i.e. chemotaxis) and
by being cytotoxic at higher concentrations [16–18]. We have recently
shown that PSMα2 and PSMα3 bind to FPR2 and trigger superoxide
release in neutrophils at low nanomolar concentrations. In addition,
at high nanomolar concentrations they display cytotoxicity selectively
on apoptotic neutrophil membranes and this occurs in an FPR2
independent manner [18].
In this study, we investigated the structural–functional relationship
for peptide activation of the FPRs in neutrophils. We found that
both the N- and C-terminus of PSMα2 are essential for cytotoxicity,
whereas the C-terminus could be removed without any major loss
in the ability to induce superoxide release. However, the C-terminus
plays a critical role in determining receptor preference for FPR2 upon
neutrophil activation.
2. Materials and methods
2.1. Reagents
Isoluminol was purchased from Sigma-Aldrich and horseradish
peroxidase (HRP) from Roche Diagnostics (Bromma, Sweden). The
PSMα2-peptide and its variants were synthesized by an American
Peptide Company (Sunnyvale, CA). All peptide stocks were made
in DMSO and further dilutions were made in Krebs-Ringer phosphate
buffer containing glucose (10 mM), Ca2+ (1 mM) and Mg2+ (1.2 mM)
(KRG, pH 7.3). WRWWWW (WRW4) was from Genscript Corporation
(Scotch Plains, NJ, USA) and Cyclosporin H (CysH) was kindly provided
by Novartis Pharma (Basel, Switzerland). Ficoll-Paque was obtained
from Amersham Biosciences. The FPR2 speciﬁc gelsolin-derived
inhibitory peptide PBP10 (gelsolin residues 160–169; [19]) was
synthesized by CASLO Laboratory (Lyngby, Denmark). RPMI 1640,
fetal calf serum (FCS), PEST and G418 were from PAA Laboratories
GmbH, Austria. Annexin V-FLUOS was from Roche Diagnostics
(Mannheim, Germany) and ToPro3 from Invitrogen, Molecular Probes
(Eugene, OR). The ﬂuorescent peptides WKYMVm (Cy5 labeled) and
fNleLFNleYK (FITC labeled) were from Phoenix Pharmaceuticals(Berlingame, CA, USA) and Invitrogen, Molecular Probes (Eugene, OR),
respectively.
2.2. Overexpression of wild type FPRs and FPR1/FPR2tail chimeric receptor in
HL-60 cells
The procedures used to obtain stable expression of FPR1 and FPR2
in undifferentiated HL-60 cells have been previously described [20].
To prevent possible auto-differentiation due to the accumulation of
differentiation factors in the culture medium, cells were passed twice
a week before they reached a density of 2 × 106 cells/ml. At each pas-
sage, an aliquot of the cell culture was centrifuged, the supernatant
was discarded and the cell pellet was resuspended in fresh medium
RPMI 1640 containing FCS (10%), PEST (1%), and G418 (1 mg/ml).
A 3xHA-tagged FPR1/FPR2tail chimeric receptor was constructed as
follows: 3xHA-FPR1 and 3xHA-FPR2 in pCDNA3.1 (+) were purchased
from the cDNA Resource Center at the University of Missouri-Rolla and
the KpnI–XhoI fragments that contain the entire 3xHA tagged receptors
were subcloned in the pCI expression vector (Clontech). The KpnI–PvuII
DNA fragment of pCI-3xHA-FPR1 containing the C-terminal cytoplasmic
region of FPR1was excised and replaced by the corresponding fragment
(amino acid 296–351) retrieved from 3xHA-FPR2 in the pCI vector after
digestion with KpnI and PvuII. The nucleotide sequence encoding the
3xHA-tagged FPR1/FPR2tail chimeric receptor was further excised from
pCI by XbaI and NheI and inserted in the pEFneo expression vector
cleaved by Xba I.
2.3. Isolation of human neutrophils from peripheral blood
Blood neutrophils were isolated, as described by Böyum [21], from
buffy coats from healthy volunteers. After dextran sedimentation at 1
×g, hypotonic lysis of the remaining erythrocytes, the neutrophils
obtained by centrifugation in a Ficoll-Paque gradient were washed
twice in KRG. The cells were resuspended in KRG (1 × 107/ml) and
stored on ice until use.
2.4. Measurement of superoxide anion production
Theproductionof superoxide anionby theneutrophil NADPH-oxidase
was measured by isoluminol-ampliﬁed chemiluminescense (CL) in a six-
channel Biolumat LB 9505 (Berthold Co, Wildbad, Germany) as
described earlier [22,23]. In short, 2 × 105/ml neutrophils were
mixed (in a total volume of 900 μl) with HRP (4 U) and isoluminol
(6 × 10−5 M) in KRG, pre-incubated at 37 °C for 5 min, after which
the stimulus (100 μl) was added. The light emission was recorded
continuously. When required, the speciﬁc receptor inhibitors were
included in the CL mixture for 5 min at 37 °C before stimulation. By
direct comparison of the SOD inhibitable reduction of cytochrome
C and SOD inhibitable CL, 7.2 × 107 counts were found to correspond
to a production of 1 nmol of superoxide (a millimolar extinction
coefﬁcient for cytochrome C of 21.1 was used).
2.5. Assessment of PSMα2 peptides-induced cytotoxicity on apoptotic
neutrophils
Freshly isolated neutrophils were resuspended in RPMI 1640
medium supplemented with 10% FCS and 1% PEST to a density of
5 × 106 cells/ml. Cells (200 μl) were incubated at 37 °C in 5% CO2
for 20 h to allow a part of the neutrophil population to spontaneously
go into apoptosis [24,25]. Themixed neutrophil populationwaswashed
and resuspended in 100 μl Annexin V binding buffer (10 mM Hepes,
140 mM NaCl, 2.5 mM CaCl2, pH 7.4) with addition of Annexin
V-FLUOS (2 μl). Samples were stained with Annexin V-FLUOS in the
dark for 5 min at ambient temperature, after which ToPro3 was
added and the staining was continued for another 5 min. Interaction
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examination with an Accuri C6 ﬂow cytometer (Accuri, UK).
2.6. Determination of changes in cytosolic calcium
Cells were resuspended at a density of 5 × 107 cells/ml in KRG
containing 0.1% BSA and loaded with 2 μM Fura 2-AM (Molecular
Probes, Eugene, OR) for 30 min at RT. The cells were then washed and
resuspended in KRG at a density of 2 × 107 cells/ml. The amount of
cells used in the assay was 2 × 106 cells/measuring cuvette. Calcium
measurements were carried out with a PerkinElmer ﬂuorescence
spectrophotometer (LS50) with excitation wavelengths of 340 and
380 nm, and an emission wavelength of 509 nm. The transient
rise in intracellular calcium is presented as a ratio of ﬂuorescence
changes (340:380 nm) [26].
2.7. Binding of FPR ligands
Ligand binding to the FPR1/FPR2tail chimeric receptor was
determined using a Cy5-conjugated hexapeptide (Cy5-WKYMVm)
and a FITC-labeled formylated peptide (FITC-fNleLFNleYK) with
preferences for FPR2 and FPR1, respectively. HL-60 cells overex-
pressing the chimeric receptor (2 × 106 cells/ml) were incubated
with the ﬂuorescent peptides in the absence or presence of unlabeled
FPR ligands. The cells were incubated with the labeled peptides on ice
for 45 min and the amount of cell bound ﬂuorescence was determined
and expressed as themean ﬂuorescence intensity (MFI) using an Accuri
C6 ﬂow cytometer (Becton Dickinson Sparks, MD, USA).
3. Results
3.1. A C-terminally truncated PSMα2 peptide loses its cytotoxic activity but
retains pro-inﬂammatory activity
Nanomolar concentrations of the peptide PSMα2 have been shown
to trigger pro-inﬂammatory neutrophil responses, such as activation
of the superoxide generating NADPH-oxidase, and this activation is
mediated through FPR2 [18]. In addition, the full length PSMα2
peptide (hereafter referred to as PSMα21–21) at high nanomolarFig. 1. PSMα21–16 is not cytotoxic to apoptotic neutrophils. A) Primary human neutrophils w
apoptosis (Annexin V+ToPro3−; lower right in the two control ﬁelds without added peptide
each ﬁeld) as assessed by Annexin V-FLUOS and ToPro3 staining by ﬂow cytometry. Incubat
but not PSMα21–16 (800 nM; lower panel) for 30 min resulted in a necrotic shift of almost a
shown. B) The cytotoxic effect of different PSMα21–21 derivatives (800 nM ﬁnal concentrat
30min afterwhich the cells were subjected for ﬂow cytometry analysis. Control cells received b
by one-way ANNOVA with Dunnett's comparisons to control.concentrations was cytolytic, with effects primarily on apoptotic
neutrophils (Fig. 1A top panel and B). Based on the observation
that the speciﬁc FPR2 inhibitor PBP10 had no effect on the ability of
the peptide to permeabilize the membranes of apoptotic neutrophils,
we concluded that the cytotoxic effect occurs independent of
FPR2 [18].
To gain further insight into the mechanism underlying the pro-
inﬂammatory and cytotoxic activity of PSMα21–21, we designed a series
of peptide variants (Table 1). PSMα21–16, a truncated peptide in which
the ﬁve most distant (the C-terminus) amino acids in PSMα21–21 were
omitted, lacked cytotoxic effects on apoptotic neutrophils (Fig. 1A
lower panel and B). The ability to activate neutrophils was retained,
however, although with reduced potency (Table 1). The C-terminal
part of PSMα21–21, required for the cytotoxic effect, was not alone
sufﬁcient to mediate the cytoxic activity, as illustrated by the fact that
the N-terminally truncated peptides PSMα217–21 or PSMα212–21 did
not have cytotoxic effects on apoptotic neutrophils (Fig. 1B). The two
peptides lacking the N-terminal amino acids were also unable to
activate neutrophils to produce superoxide anions (Table 1). Taken
together, these data show that the full length of PSMα21–21 is required
for cytotoxicity and that the peptide PSMα21–16, lacking the C-terminus,
retains the pro-inﬂammatory activity.
3.2. The residues 5–16 of the PSMα2 peptide are critical determinants for
receptor preference
We have earlier shown that the activation of the NADPH-oxidase
in neutrophils triggered with the full length PSMα21–21 peptide is
inhibited by FPR2 selective antagonists/inhibitors. This shows a receptor
preference for FPR2 and accordingly, the response induced is virtually
insensitive to the FPR1 speciﬁc antagonist CysH [18]. Similar to the full
length PSMα21–21, the PSMα21–16 triggered neutrophil activation was
also inhibited by the FPR2 inhibitor PBP10 (Fig. 2A). The effect of
the FPR1 antagonist CysH was fairly small (Fig. 2A), suggesting that
FPR2 is the preferred receptor also for PSMα21–16. This suggestion is
supported by the fact that the response was also inhibited by WRW4,
another FPR2 selective antagonist (data not shown).
To gain insight into the structure–function relationship of PSMα2
in activating neutrophils, peptides lacking larger segments of theere incubated over night to allow approximately 30% of the cells to spontaneously enter
). In this cell population around 15% were necrotic (Annexin V+ToPro3+; upper right in
ion of this mixed cell population with the full length PSMα21–21 (800 nM; upper panel)
ll apoptotic cells. Representative plots out of at least ﬁve independent experiments are
ion) was examined by incubation of peptides with the mixed cell population on ice for
uffer only. Data are presented as % necrotic of cell, mean+SEM (n=3). *p b 0.05 analyzed
Table 1
Forsman H et al.
Description of the PSMα2 and fMIFL peptides.
PSMα21–21
peptide
variants
Peptide sequence Number
of amino
acids
EC50 (nM) 95% (CI)
PSMα21–21 f-MGIIAGIIKFIKGLIEKFTGK 21 50 30–90
PSMα21–16 f-MGIIAGIIKFIKGLIE 16 220 150–310
PSMα21–12 f-MGIIAGIIKFIK 12 750 440–1280
PSMα21–10 f-MGIIAGIIKF 10 1550 980–2440
PSMα21–5 f-MGIIA 5 N2000 –
PSMα212–21 f-KGLIEKFTGK 10 – –
PSMα217–21 f-KFTGK 5 – –
Chimeric
fMIFL/PSM
peptides
Peptide sequence Number
of amino
acids
EC50 (nM) 95% (CI)
fMIFL f-MIFL 4 0.12 0.09–0.17
fMIFL-PSM5–10 f-MIFLAGIIKF 10 0.40 0.23–0.67
fMIFL-PSM5–12 f-MIFLAGIIKFIK 12 0.60 0.38–0.95
fMIFL-PSM5–16 f-MIFLAGIIKFIKGLIE 16 0.73 0.51–1.05
Peptide sequences and the number of lengths (number of amino acids) are shown. The
activating potencies of the peptides for neutrophil FPRs were examined in the superoxide
release assay. Human neutrophils were stimulated with different concentrations of
peptides and dose-dependent superoxide release was recorded. The EC50 values and 95%
conﬁdence intervals (CI) were calculated from the normalized peak superoxide release
from three independent experiments. Data are shown as the mean EC50 in (nM). “–”:
poor or inactive in the assay.
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additional amino acids deleted from the C-terminus of PSMα21–16)
activated neutrophils to release superoxide with an EC50 value only
slightly higher than that of PSMα21–16 (Table 1), suggesting
that these four amino acids do not signiﬁcantly contribute to theFig. 2. Changed receptor preference for the PSMα21–21 derivatives. A) Primary human neutrophil
or the FPR2 speciﬁc inhibitor PBP10 (1 μM, gray bars) for 5min at 37 °C. The PSMα21–16 peptide
anionswas recorded continuously. Thepeak values of the responsesweredetermined, compared a
B–D) Effect of buffer (control; solid lines), CysH (1 μM; dotted lines), PBP10 (1 μM; dash
PSMα2 peptides; B) PSMα21–12 (1 μM, ﬁnal concentration); C); PSMα21–10 (1 μM, ﬁnal conce
is indicated by the arrows. Representative curves out of more than ﬁve times are shown. Abscactivation potency. They do, however, contribute to the choice of
receptor, as shown by the fact that the neutrophil response in-
duced by PSMα21–12 was inhibited to the same degree by the
FPR1 speciﬁc inhibitor CysH and the FPR2 speciﬁc inhibitor PBP10
(Fig. 2B). When the concentration of PSMα21–12 was lowered, the
FPR1 selective inhibitor was actually slightly more potent than
the FPR2 speciﬁc inhibitor (data not shown). Further, when the
two inhibitors were combined, the inhibition was total (Fig. 2B),
suggesting that PSMα21–12 is a dual agonist that is recognized by
both FPR1 and FPR2. The PSMα21–10 and PSMα21–5 peptides, with
additional deletions of amino acids from the C-terminus, retained
the capacity to activate neutrophils to produce superoxide. EC50 values,
however, reﬂected lower potency (Table 1). More importantly, the re-
sponses induced by these peptides (PSMα21–10 and PSMα21–5) were
totally inhibited by CysH but not by PBP10 (Fig. 2C, D), suggesting
that FPR1 was the preferred receptor.
The receptor preference and relative potency of the PSMα2 variants
were also determined with FPR1 and FPR2 overexpressing cells and the
results obtained with primary neutrophils were conﬁrmed. In agree-
ment with the receptor preference observed in neutrophils expressing
both receptors, PSMα21–16 at 1 nM concentration triggered a robust
calcium transient in FPR2 overexpressing cells, whereas no such activity
was induced in cells overexpressing FPR1 (Fig. 3). In addition, the
shorter peptides PSMα21–10 and PSMα21–5 evoked a transient rise in
calcium solely in FPR1 overexpressing cells (Fig. 3). With respect to
potency, a much higher concentration of PSMα21–5 was needed to
trigger a calcium response in FPR1 overexpressing cells, compared to
the concentration needed for PSMα21–16 to induce a response in FPR2
overexpressing cells (Fig. 3). In agreement with the dual agonism of
PSMα21–12 in neutrophils (Fig. 2B), this peptide triggered a calcium
response in both FPR1- and in FPR2 overexpressing cells (Fig. 3). Taken
together, these data show that the presence of the C-terminal aminos were left untreated or incubatedwith the FPR1 speciﬁc antagonist CysH (1 μM, black bars)
at indicated concentrations was added and the neutrophil production/release of superoxide
ndexpressed as percent of the control values (without any inhibitor;mean+SEM(n=5)).
ed lines) or both inhibitors together on the superoxide release induced by different
ntration); D) PSMα21–5 (2.5 μM, ﬁnal concentration). The time point for peptide addition
issa, time of study (min); ordinate, superoxide release in arbitrary units (Mcpm).
Fig. 3.Transient changes in cytosolic calcium induced by the PSMα21–21 derivatives in
HL-60 cells overexpressing FPR1 or FPR2. Fura-2 labeled HL-60 cells overexpressing
FPR1 (left panel) or FPR2 (right panel) were stimulated with PSMα21–21 derivatives
at different concentrations as indicated. The time points for peptide addition are
indicated by arrows and an increase in cytosolic free Ca2+ was monitored by the
change in Fura-2 ﬂuorescence. Representative experiments out of at least three are
shown. Abscissa, time of study (s); ordinate, ﬂuorescence (arbitrary units).
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pro-inﬂammatory activity, but constitutes a critical determinant for the
potency and for the FPR2 preference of the peptide.3.3. The FPR1 agonist fMIFL is also recognized by FPR2 when linked to
PSMα25–16
The S. aureus-derived formylated peptide fMIFL is a very potent
activator of neutrophil superoxide production/release, with an EC50
value of ≈0.1 nM (Table 1). In accordance with the known receptor
preference of this peptide, the fMIFL response was totally inhibited by
the FPR1 selective antagonist CysH (Fig. 4A inset), whereas the response
was virtually insensitive to the FPR2 speciﬁc inhibitor PBP10 (Fig. 4B
inset). It is thus clear that FPR1 is the preferred receptor for fMIFL. To
further investigate the impact of the C-terminus of PSMα21–16 with
respect to receptor preference, we designed several fMIFL-PSMα2
chimeric peptides (hereafter referred to as fMIFL-PSM peptides) all
having identical N-termini, but with “tails” containing different
numbers of amino acids derived from PSMα21–16 (Table 1). Very robust
superoxide activity was induced by fMIFL-PSM5–16, in which the PSM
amino acid 5–16 was attached to fMIFL (Fig. 4A, B). It should be noticed
that not only the activation potency of fMIFL-PSM5–16 was changed in
comparison to fMIFL, but also the receptor recognition proﬁle differed
from that of the original fMIFL peptide. The activity induced by the
fMIFL-PSM5–16 peptide was only partly inhibited by CysH (Fig. 4A, D).
The inhibition mediated by PBP10 was also only partial (Fig. 4B, D),
suggesting that this chimeric fMIFL-PSM peptide engaged both FPR1
and FPR2. The shift in receptor preference was conﬁrmed in FPR2 over-
expressing cells in which fMIFL-PSM5–16 was readily active (Fig. 4C).
Higher concentrations of this peptide induced a calcium response also
in FPR1 overexpressing cells, suggesting that fMIFL-PSM5–16 has a
preference for FPR2 but is recognized by both receptors. This was
further supported by the fact that neutrophil superoxide release
induced by this peptide was completely abolished by the combined
action of CysH and PBP10 (data not shown).Shorter chimeric fMIFL-PSM peptides (i.e., fMIFL-PSM5–12 and
fMIFL-PSM5–10) also activated neutrophils to release superoxide, with
EC50 values very similar to those of the fMIFL-PSM5–16 peptide
(Table 1). The fMIFL-PSM5–12 peptide was also a dual agonist, as illus-
trated by the fact that neither CysH nor PBP10 alone inhibited the
response (Fig. 4D). In contrast, the activity induced by fMIFL-PSM5–10
was fully inhibited by CysH, whereas PBP10 was without effect
(Fig. 4D), suggesting that FPR1 was the preferred receptor.
In conclusion, there was a clear difference in receptor preference
between fMIFL-PSM5–10 and fMIFL-PSM5–12 in that fMIFL-PSM5–10
activated neutrophils primarily through FPR1, whereas fMIFL-PSM5–12
was a dual agonist as the responsewas inhibited by the combined action
of CysH and PBP10 (Figs. 4D, 5A). To investigate the role of the amino
acids Ile at position 11 and Lys at position 12 present in the fMIFL-
PSM5–12, but absent in fMIFL-PSM5–10, we designed peptide variants
and determined the receptor preference of these variants through the
inhibitory effects of CysH and PBP10. The inhibition proﬁle for fMIFL-
PSM5–12 was not changed when Lys in position 12 was exchanged for
a Gln (Fig. 5B). The dual agonismwas, however, lostwhen Ile in position
11 was omitted or exchanged for an Ala, as the response induced by
these peptideswasmarkedly inhibited by CysH, suggesting a preference
for FPR1 over FPR2 (shown for the peptide with Ile omitted in Fig. 5B).
These variants were as potent as the fMIFL-PSM5–12 peptide in trigger-
ing superoxide release in neutrophils (data not shown). Taken together,
the data strongly suggests that size matters when it comes to FPR
preference, and the C-terminal part of the peptides constitutes a key
determinant for FPR2 interaction.
3.4. A chimeric receptor in which the cytoplasmic tail of FPR1 was replaced
by that in FPR2 recognizes FPR2 agonists
The calculations of the proposed agonist-binding pocket for fMet
peptides present in FPR1 suggest that there is room for four or maybe
ﬁve amino acids [15], but the results presented in this study show that
the receptor preference is determined also by parts of the agonists
that most probably are located outside of the proposed binding pocket.
Changed binding properties could possibly also be induced by structural
changes of the receptors, and these changes might involve domains of
the receptors not directly engaged in agonist binding. This suggestion
gains support from earlier published results with an FPR1 chimeric re-
ceptor having a cytoplasmic tail identical to that of FPR2 (amino acids
296–351; Fig. 6A). This chimeric receptor was no longer able to respond
to fMIFL, an FPR1 speciﬁc agonist ((19) and Fig. 6B). This ﬁnding
supports the suggestion that the ligand-binding characteristics may be
inﬂuenced by parts of the receptor not directly involved in agonist
binding. We have now extended these ﬁndings when showing that
the loss of function of the FPR1/FPR2tail chimeric receptor is also accom-
panied by a gain of function, as the fMIFL-PSM5–16 hybrid peptide,
shown to be a dual agonist for the two FPRs, triggered an increase
in [Ca2+]i in cells expressing the chimeric FPR1/FPR2tail receptor
(Fig. 6C). Moreover, the response induced by fMIFL-PSM5–16 in cells
expressing the FPR1/FPR2tail receptor was completely abolished by
PBP10 (an FPR2 speciﬁc inhibitor) but not by CysH (an FPR1 speciﬁc
inhibitor; Fig. 6C). Taken together this suggests that the chimeric
receptor (FPR1/FPR2tail) has a preference for FPR2 ligands, which
gained further support from the activation proﬁle obtained when
using several other well-characterized agonists that have been shown
to be either dual agonists or speciﬁc receptor agonists for FPR1 and
FPR2, respectively [5,6]. The receptor preferences of all ligands used
were conﬁrmed using FPR1- and FPR2 overexpressing cells (Fig. 6D),
and all dual and FPR2 speciﬁc agonists were found to induce a rise in
[Ca2+]i in cells expressing the chimeric FPR1/FPR2tail receptor, whereas
no such response was induced by FPR1 speciﬁc agonists (Fig. 6D).
Binding experiments performed with ﬂuorescent-labeled FPR
agonists support the suggestion about the changed receptor preference.
Accordingly, we could not show any binding of the ﬂuorescent FPR1
Fig. 4. Receptor preference for chimeric fMIFL-PSMα2 peptides. A, B) In order to compare the receptor preference for fMIFL (2 nM; insets) with the chimeric fMIFL-PSM5–16 peptide
(0.3 nM), human neutrophils were activated with the two peptides in the presence or absence of receptor selective inhibitors CysH (1 μM and selective for FPR1; A) or PBP10
(1 μMand selective for FPR2; B). The time points for agonist addition are indicated by arrows. The FPR1 selective inhibitor reduced the neutrophil response to fMIFL substantially
but had very little effect on the response induced by the chimeric fMIFL-PSM5–16 peptide (A). The FPR2 selective inhibitor reduced the neutrophil response induced by the chimeric fMIFL-
PSM5–16 but had no effect on the response induced by fMIFL (B). Representative experiments out of at least three are shown. C) Fura-2 labeled HL-60 cells overexpressing FPR1 (solid line)
or FPR2 (dashed line) were stimulated with the chimeric fMIFL-PSM5–16 peptide (0.5 nM). The time point for peptide addition is indicated by an arrow and the increase in free cytosolic
Ca2+wasmonitored by the Fura-2ﬂuorescence. Representative experiments out of at least three are shown. Abscissa, time of study (s); ordinate,ﬂuorescence (arbitrary units). D)Human
neutrophils were left untreated or pre-incubated together with the FPR1 speciﬁc antagonist CysH (1 μM, black bars) or the FPR2 speciﬁc inhibitor PBP10 (1 μM, gray bars) for 5 min at
37 °C. Chimeric fMIFL-PSM peptides (0.3 nM ﬁnal concentration) were added and the neutrophil production/release of superoxide anions was recorded continuously. The peak values
of the responses were determined, compared and expressed as percent of the control values (without any inhibitor; mean + SEM (n = 5)) for fMIFL-PSM5–16, fMIFL-PSM5–12, and
fMIFL-PSM5–10, respectively.
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tor (data not shown) whereas the dual agonist (Cy5-WKYMVm) binds.
This binding was speciﬁc as illustrated by the fact that a non-labeled
peptide inhibited binding and in addition this bindingwas also inhibited
by the FPR2 speciﬁc ligandWKYMVM whereas the FPR1 speciﬁc ligand
fMIFL was without any effect (Fig. 7).Fig. 5. Receptor preference for the chimeric peptide variants of fMIFL-PSM5–12. A) Human neutr
or the FPR2 speciﬁc inhibitor PBP10 (1 μM)orboth inhibitors together for 5min at 37 °C. The tim
Representative experiments out of at least three are shown. Abscissa, time of study (min); o
untreated or pre-incubated with the FPR1 speciﬁc antagonist CysH (1 μM, black bars) or FPR2
2 nM ﬁnal concentration) or its variants (Lys at position 12 was exchange to Gln, and Ile at po
and the neutrophil production/release of superoxide anions was recorded continuously. Peptid
of the responses were determined and expressed as percent of the control values without inhi4. Discussion
The FPRs play important roles in the defense reaction against
microbial infections and in regulation of inﬂammation. Their basic
function is to recognize danger signals in the form of N-formylated
peptides and various other inﬂammatory mediators [5,16,28]. Theophils were left untreated or pre-incubatedwith the FPR1 speciﬁc antagonist CysH (1 μM)
epoint for addition of the chimeric fMIFL-PSM5–12 peptide (2nM) is indicated by an arrow.
rdinate, superoxide release in arbitrary units (Mcpm). B) Human neutrophils were left
speciﬁc inhibitor PBP10 (1 μM, gray bars) for 5 min at 37 °C. The fMIFL-PSM5–12 (control,
sition 11 was either exchanged to Lys or deleted) was added at 2 nM ﬁnal concentration
e sequences of the fMIFL-PSM5–12 variants are shown in the lower panel. The peak values
bitor, mean + SEM (n = 3).
Fig. 6.Agonist activation proﬁle of the chimeric FPR1/FPR2tail receptor. A) Schematic drawing of the human chimeric FPR1/FPR2tail receptor inwhich a part of the seventh transmembrane
region and the entire cytoplasmic tail of FPR1were replaced by the corresponding residues in FPR2 (296–351, ﬁlled circles in black). The opened circles in gray represent the amino acids in
FPR1. B, C) Fura-2 labeledHL-60 cells overexpressing the chimeric FPR1/FPR2tail receptor were stimulatedwith the dual FPR1/FPR2 agonistWKYMVm (10 nM) and the FPR1 agonist fMIFL
(100 nM) in (B), and with the chimeric fMIFL-PSM5–16 peptide (10 nM) in (C). The time point for peptide addition is indicated by an arrow and the increase in free cytosolic Ca2+ was
monitored by the change in Fura-2 ﬂuorescence. As shown in (C), the fMIFL-PSM5–16 induced response was not inhibited by PBP10 (1 μM) or by CysH (1 μM). Representative experiments
out of at least three are shown. Abscissa, time of study (s); ordinate, ﬂuorescence (arbitrary units). D) Summary of the results obtained with HL-60 cells overexpressing wild type FPR1,
FPR2 or chimeric FPR1/FPR2tail receptor upon stimulationwith different earlier characterized FPR agonists. Positive (+), a transient increase in intracellular Ca2+ is induced; negative (−),
no Ca2+ response is induced, even with concentrations exceeding those typically used to induce a response in HL-60 cells overexpressing wild type FPRs. The FPR agonists examined
include, the FPR1 speciﬁc agonists fMLF (100 nM) and fMIFL (100 nM), the FPR2 speciﬁc agonists WKYMVM (100 nM), MMK1 (100 nM) and F2Pal10 (1 μM), and the FPR1/FPR2 dual
agonists Comp43 (1 μM),WKYMVm (10 nM) and fMIFL-PSM5–16 (10 nM). Three independent experiments were performed for all agonists and similar activation patterns were obtained.
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peptides, but they possess somewhat different recognition proﬁles.
It has been known for long that FPR1 recognizes N-formylatedFig. 7. Ligand binding to the chimeric FPR1/FPR2tail receptor. Ligand binding to
the FPR1/FPR2tail chimeric receptor was determined using a Cy5-conjugated hexapeptide
(Cy5-WKYMVm) with preferences for FPR2. Undifferentiated HL-60 cells overexpressing
the chimeric receptor (2 × 106 cells/ml) were incubated with the ﬂuorescent peptide
(1 nM ﬁnal concentration) in the absence or presence of unlabeled FPR ligands (100 nM
ﬁnal concentration). The cells were incubated on ice and the amount of cell-bound
ﬂuorescence was examined by ﬂow cytometry and expressed as the mean ﬂuorescence
intensity (MFI). The inset summarizes the inhibitory effects of the FPR2 agonist WKYMVM
and the FPR1 agonist fMIFL on Cy5-WKYMVm binding when compared to the values
of speciﬁc binding obtained with cells incubated with the ﬂuorescent peptide and
WKYMVm together (0%) and with the Cy5-labeled peptide alone (100%), respectively
(mean values + SEM; n = 4).methionyl (N-fMet) peptides generated by bacteria or mitochondria,
forming the molecular basis for professional phagocytes (neutrophils
and monocytes/macrophages) to sense gradients of chemoattractants
and to migrate directionally to the sites of infection and inﬂammation
[7,8]. Following the deorphanization of FPR2 [20,29,30], a receptor
closely related to FPR1, a number of different non-formylated peptides
and small molecules were found to be recognized by this receptor,
but despite the large similarities with FPR1, none of the high afﬁnity
ligands initially described for FPR2 belonged to the group of peptides
starting with an N-fMet group [5,6]. The recent characterization of pep-
tides from mitochondria [1] and a group of phenol-soluble modulins
(PSMs), a family of peptides that are secreted by a dedicated transport
system in pathogenic strains of S. aureus, changed this situation as
these peptides start with an N-fMet and have proinﬂammatory proper-
ties that are mediated primarily via interaction with FPR2 [16,18]. It is
thus clear that both FPR1 and FPR2 have the ability to recognize
N-fMet peptides but with different binding proﬁles depending on the
amino acids linked to the initial fMet moiety.
In this study, we investigated the structural–functional relationship
of PSMα2 peptides in interaction with FPR1 and FPR2, using a rapid
and sensitive functional assay (an NADPH-oxidase activity assay). This
assay allows us to fairly rapidly measure and quantify receptor speciﬁc
activities using many different agonist concentrations in the presence
and absence of deﬁned antagonists, and by that the technique is
well suited to determine receptor preference for the peptide agonists.
The signaling molecules downstream of the FPRs are many and the
pathways are complicated [5,6], but since our work is focused on the
receptor preference for the PSM-peptides, cells overexpressing FPR1
or FPR2 and a read out system (the PLC/Ca2+ route) that picks up a
signal as close as possible to the receptors were used to conﬁrm the
receptor selectivity. Our results clearly show that the C-terminus of
PSMα2 is of prime importance for activation of FPR2 by this peptide,
as deletion of the C-terminal region generates peptide variants of
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over a dual FPR1/FPR2 agonism to a preference for FPR1 for the
shortest peptides. The importance of the C-terminus of PSMα2 in
FPR2 interaction is further supported by the fact that an attachment
of a twelve-amino-acid long sequence (amino acids 5–16) in PSMα2
to the potent FPR1 agonist fMIFL give rise to a dual agonist that acti-
vates both FPR1 and FPR2. A peptide that is devoid of the N-terminal
part has no FPR-activating effects, and the sequence starting with
an N-formylated methionyl group is required for the interaction
with both FPR1 and FPR2. The amino acids of the N-terminus in
PSMα21–16 are identical to those in PSMα21–5 and PSMα21–10,
respectively, yet the peptides activate different receptors. It is
known from earlier studies that the binding pocket in FPR1 has
room for no more than ﬁve amino acids [15], and when the charge
of an FPR1 selective pentapeptide is reduced, such peptides will in-
teract also with FPR2 [31], even if FPR1 is still the preferred receptor
[32]. This means that receptor preference is not determined solely by
the amino acids that have access to the presumed agonist binding
pocket of the receptor, but in part also by amino acids in the peptide
that do not have direct access to the binding pocket.
In addition to the FPR2-mediated pro-inﬂammatory activity, PSMα
peptides also exert cytotoxicity on leukocytes [16,18]. This is a result
of the PSMα peptide adopting an amphipathic α-helical structure,
which may contribute to membrane disruption and cytotoxicity. Our
results obtained using PSMα2 variants suggest that the full-length
peptide is required for cytolytic activity on apoptotic neutrophils,
but since the N-terminus is the part that is essential for neutrophil
activation there is no direct link between the cytolytic and the pro-
inﬂammatory activities. The lack of cytolytic activity of the C-terminal
truncated peptides may be related to a reduced capacity to form a
α-helix, although it has been suggested that theα-helicity is not corre-
lated with peptide functions, including cytolytic activity [31]. In line
with our ﬁndings, a recent study using an alanine substitution screen
of PSMα3, a closely related S. aureus modulin, demonstrates that the
physicochemical property of the amino acids present in C-terminus of
PSMα3 (i.e., Lys6, Lys12, Lys17, Asn21 or Asn22) is crucial for the
FPR2 binding capacity [31]. It should be noticed, however, that no
change in the receptor preference was described, meaning that all the
PSMα3 peptide variants tested preferred FPR2 over FPR1. This suggests
that the C-terminus of PSMα3 is important for the potency, but not for
receptor preference [31]. With respect to potency, our results support
the role of the C-terminus, as illustrated by the fact that the truncated
peptide PSMα21–16 retains FPR2 selectivity, but with a substantially
reduced potency compared to PSMα21–21. Whether this is due to a
direct interaction of the C-terminus of the peptide with the receptor,
or more indirect effects due to an interaction with the membrane,
remains to be determined. Although PSMα2 and PSMα3 share a
common three-dimensional structure, their primary peptide sequences
are very different, and it is possible that the C-termini of PSMα2
and PSMα3 are differently involved in FPR interaction. More studies
attempting to understand the structure–function relationship of
individual PSM peptides should help elucidate whether a common
mechanism is applicable for all PSM peptides.
With respect to receptor preference it is obvious that the Ile at
position 11 in the PSMα2 peptide is of prime importance, as illustrated
by the preference change from FPR2 to FPR1 when this non-polar
residue was omitted or exchanged for an Ala, but it is hard to ﬁt this
into the binding model for the FPRs. Receptor mutagenesis studies
with FPR1 suggest that amino acids in both extracellular and transmem-
brane domains are of importance for agonist binding [10,12,14,33],
but only a limited number of these (i.e., the ones in positions 84, 85,
89, 90 102, and 103) differ between FPR1 and FPR2. Recent computer
modeling and site directed mutagenesis experiments have suggested
that the amino acid difference in position 281 (an Asp in FPR2 and a
Gly in FPR1) is of importance for the selectivity in agonist binding [32],
and an exchange of the Asp in FPR2 for a Gly may change the activationpotency of certain fMet containing peptides [32]. The chimeric receptor
approach has also been used to deﬁne the molecular determinants
involved in agonist recognition [5,6], and it is evident that an exchange
of receptor parts that are not directly involved in agonist binding may
also affect the selectivity. In line with this, it has been shown that a
chimeric receptor in which the cytoplasmic tail in FPR1 was replaced
by that present in FPR2 possesses reduced the potency of the FPR1
agonist fMLF [34], and a chimeric receptor in which the second intra-
cellular loop or the cytoplasmic tail of FPR1 was exchanged for the
corresponding parts of FPR2 actually results in an enhanced calcium
response to FPR2 agonists [35]. We also recently described that a
chimeric FPR1/FPR2tail receptor in which the cytoplasmic tail in
FPR1 was replaced with that from FPR2 (amino acids 296–351),
was unable to recognize FPR1 agonists [19]. Interestingly this chimeric
receptor also gained function, a conclusion drawn from our results
showing that all FPR2 agonists investigated activated this receptor.
It is not very likely that the cytoplasmic tail is directly involved in
ligand binding, but rather that it affects distant parts of the receptor
involved in agonist recognition. Taken together, these observations
suggest an importance of the composition/structure of cytosolic
receptor domains for ligand binding. This is supported by the fact
that a chimeric FPR1/FPR2tail receptor, containing all the structural
elements supposed to be of importance for recognition of FPR1 agonists,
is activated by agonists that have FPR2 as their prime receptor. It is rea-
sonable to assume that the formation of a high-afﬁnity agonist-binding
site is a highly dynamic process that must be apposed by coordinate
folding of multiple non-contiguous domains, including the sites that
are directly involved in binding. This indicates that very similar binding
structures on themolecular level may be present in FPR1 and FPR2, and
that binding is affected by more general conformational differences
between the two receptors. The fact that FPR2-selective agonists, but
not FPR1-selective agonists, activate cells expressing the chimeric
receptor in which the cytoplasmic tail of FPR1 has been exchanged for
that of FPR2, support this suggestion.
Although the two FPRs share large sequence similarities and
induce almost identical neutrophil responses, we have earlier
described some fundamental differences that distinguish these
receptors from each other. One such characteristic is that the two
receptors differ in their sensitivity to allosteric modulation from the
cytosolic side of the plasma membrane. We have earlier suggested
this as the mechanism at hand for the FPR2 selective inhibition
mediated by the gelsolin derived peptide PBP10 [19], as well as
for the FPR2 selective activation induced by the pepducin F2Pal10
(with a peptide sequence derived from the third intracellular
loop of FPR2) [36]. The fact that these FPR2 selective allosteric
modulators also inhibit and activate, respectively, the cells that
express the chimeric FPR1/FPR2tail, in which the cytoplasmic tail
of FPR1 has been exchanged for that in FPR2, suggests that very
similar binding structures on the molecular level may be present
in FPR1 and FPR2, and that interaction with allosteric modulators
is also affected by more general conformational differences between
the two receptors.
In conclusion, our data show that the length of a peptide agonist
and the structure of the FPRs together determine the activation potency
and receptor preference of a given agonist. The PSMα2 derivatives
identiﬁed, with distinct receptor preference, together with the unique
allosteric modulators for FPRs, should serve as valuable molecular
tools to approach the ligand-binding pocket and other regulatory
domains present in FPR1 vs. FPR2, as more structural information,
including crystal structures for FPRs, becomes available.
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